Altimmune (NASDAQ:ALT) Price Target Cut to $15.00 by Analysts at JMP Securities

Altimmune (NASDAQ:ALT - Free Report) had its price target decreased by JMP Securities from $25.00 to $15.00 in a research report report published on Thursday morning,Benzinga reports. JMP Securities currently has a market outperform rating on the stock.

ALT has been the topic of a number of other research reports. Wall Street Zen downgraded Altimmune from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research note on Friday, June 27th. Finally, William Blair reaffirmed a "market perform" rating on shares of Altimmune in a report on Friday, June 27th. Two analysts have rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $18.20.

Altimmune Price Performance

ALT traded down $0.19 on Thursday, reaching $4.22. The company's stock had a trading volume of 3,367,747 shares, compared to its average volume of 3,369,982. The business's 50 day moving average is $5.65 and its 200 day moving average is $5.87. Altimmune has a 1 year low of $2.90 and a 1 year high of $11.16. The stock has a market cap of $341.88 million, a price-to-earnings ratio of -3.35 and a beta of 0.47.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. Altimmune had a negative net margin of 451,200.00% and a negative return on equity of 65.44%. During the same period in the prior year, the company posted ($0.34) earnings per share. As a group, research analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of Altimmune

Several hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC boosted its position in Altimmune by 38.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 28,050 shares of the company's stock worth $202,000 after acquiring an additional 7,850 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Altimmune during the fourth quarter valued at about $88,000. Sequoia Financial Advisors LLC increased its stake in Altimmune by 34.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company's stock valued at $98,000 after buying an additional 3,500 shares during the period. Intech Investment Management LLC increased its stake in Altimmune by 36.7% during the 4th quarter. Intech Investment Management LLC now owns 46,123 shares of the company's stock valued at $333,000 after buying an additional 12,385 shares during the period. Finally, Teacher Retirement System of Texas increased its stake in Altimmune by 19.2% during the 4th quarter. Teacher Retirement System of Texas now owns 21,205 shares of the company's stock valued at $153,000 after buying an additional 3,423 shares during the period. 78.05% of the stock is currently owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.